These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37151150)

  • 61. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials.
    Damodharan S; Lara-Velazquez M; Williamsen BC; Helgager J; Dey M
    J Pers Med; 2022 May; 12(5):. PubMed ID: 35629262
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect.
    Rahal F; Capdevielle C; Rousseau B; Izotte J; Dupuy JW; Cappellen D; Chotard G; Ménard M; Charpentier J; Jecko V; Caumont C; Gimbert E; Grosset CF; Hagedorn M
    Neurooncol Adv; 2022; 4(1):vdac018. PubMed ID: 35300150
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
    Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
    Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
    Venneti S; Kawakibi AR; Ji S; Waszak SM; Sweha SR; Mota M; Pun M; Deogharkar A; Chung C; Tarapore RS; Ramage S; Chi A; Wen PY; Arrillaga-Romany I; Batchelor TT; Butowski NA; Sumrall A; Shonka N; Harrison RA; de Groot J; Mehta M; Hall MD; Daghistani D; Cloughesy TF; Ellingson BM; Beccaria K; Varlet P; Kim MM; Umemura Y; Garton H; Franson A; Schwartz J; Jain R; Kachman M; Baum H; Burant CF; Mottl SL; Cartaxo RT; John V; Messinger D; Qin T; Peterson E; Sajjakulnukit P; Ravi K; Waugh A; Walling D; Ding Y; Xia Z; Schwendeman A; Hawes D; Yang F; Judkins AR; Wahl D; Lyssiotis CA; de la Nava D; Alonso MM; Eze A; Spitzer J; Schmidt SV; Duchatel RJ; Dun MD; Cain JE; Jiang L; Stopka SA; Baquer G; Regan MS; Filbin MG; Agar NYR; Zhao L; Kumar-Sinha C; Mody R; Chinnaiyan A; Kurokawa R; Pratt D; Yadav VN; Grill J; Kline C; Mueller S; Resnick A; Nazarian J; Allen JE; Odia Y; Gardner SL; Koschmann C
    Cancer Discov; 2023 Nov; 13(11):2370-2393. PubMed ID: 37584601
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas.
    Keane L; Cheray M; Saidi D; Kirby C; Friess L; Gonzalez-Rodriguez P; Gerdes ME; Grabert K; McColl BW; Joseph B
    Neurooncol Adv; 2021; 3(1):vdab096. PubMed ID: 34485907
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
    Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
    Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.
    Erker C; Lane A; Chaney B; Leary S; Minturn JE; Bartels U; Packer RJ; Dorris K; Gottardo NG; Warren KE; Broniscer A; Kieran MW; Zhu X; White P; Dexheimer PJ; Black K; Asher A; DeWire M; Hansford JR; Gururangan S; Nazarian J; Ziegler DS; Sandler E; Bartlett A; Goldman S; Shih CS; Hassall T; Dholaria H; Bandopadhayay P; Samson Y; Monje M; Fisher PG; Dodgshun A; Parkin S; Chintagumpala M; Tsui K; Gass D; Larouche V; Broxson E; Garcia Lombardi M; Wang SS; Ma J; Hawkins C; Hamideh D; Wagner L; Koschmann C; Fuller C; Drissi R; Jones BV; Leach J; Fouladi M
    Neuro Oncol; 2022 Jan; 24(1):141-152. PubMed ID: 34114629
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M Gliomas.
    Leszczynska KB; Jayaprakash C; Kaminska B; Mieczkowski J
    Front Genet; 2021; 12():742561. PubMed ID: 34646308
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The H3K36me2 writer-reader dependency in H3K27M-DIPG.
    Yu JR; LeRoy G; Bready D; Frenster JD; Saldaña-Meyer R; Jin Y; Descostes N; Stafford JM; Placantonakis DG; Reinberg D
    Sci Adv; 2021 Jul; 7(29):. PubMed ID: 34261657
    [TBL] [Abstract][Full Text] [Related]  

  • 71. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting.
    Parekh K; LeBlang S; Nazarian J; Mueller S; Zacharoulis S; Hynynen K; Powlovich L
    Neoplasia; 2023 Mar; 37():100876. PubMed ID: 36709715
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
    Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
    Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
    Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
    J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Diffusion-weighted imaging-gadolinium enhancement mismatch sign in diffuse midline glioma.
    Ikeda K; Kolakshyapati M; Takayasu T; Amatya VJ; Takano M; Yonezawa U; Taguchi A; Onishi S; Takeshima Y; Sugiyama K; Yamasaki F
    Eur J Radiol; 2022 Feb; 147():110103. PubMed ID: 35051691
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
    Lobon-Iglesias MJ; Giraud G; Castel D; Philippe C; Debily MA; Briandet C; Fouyssac F; de Carli E; Dufour C; Valteau-Couanet D; Sainte-Rose C; Blauwblomme T; Beccaria K; Zerah M; Puget S; Calmon R; Boddaert N; Bolle S; Varlet P; Grill J
    J Neurooncol; 2018 Mar; 137(1):111-118. PubMed ID: 29198053
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
    Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
    Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5.
    Sun Y; Yan K; Wang Y; Xu C; Wang D; Zhou W; Guo S; Han Y; Tang L; Shao Y; Shan S; Zhang QC; Tang Y; Zhang L; Xi Q
    Nat Cancer; 2022 Sep; 3(9):1105-1122. PubMed ID: 35915262
    [TBL] [Abstract][Full Text] [Related]  

  • 80. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition.
    Guo Y; Li Z; Parsels LA; Wang Z; Parsels JD; Dalvi A; The S; Hu N; Valvo VM; Doherty R; Peterson E; Wang X; Venkataraman S; Agnihotri S; Venneti S; Wahl DR; Green MD; Lawrence TS; Koschmann C; Morgan MA; Zhang Q
    bioRxiv; 2024 Aug; ():. PubMed ID: 39253432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.